Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein

DNA and Cell Biology

Volumn 26, Issue 6, 2007, Pages 361-367

  Chen, Shuiping ^a   Yu, Man ^a   Jiang, Tao ^a   Deng, Yongqiang ^a   Qin, Chengfeng ^a   Qin, Ede ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DNA FRAGMENT; FREUND ADJUVANT; THIOREDOXIN; VIRUS ENVELOPE PROTEIN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DENGUE VIRUS; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BASE SEQUENCE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; ESCHERICHIA COLI; MUS;

EID: 34250819326     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.0547     Document Type: Article

References (33)

1. APT, D., RAVIPRAKASH, K., BRINKMAN, A., SEMYONOV, A., YANG, S., SKINNER, C., DIEHL, L., LYONS, R., PORTER, K., and PUNNONEN, J. (2006). Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24, 335-344.
2. BHAMARAPRAVATI, N., and SUTEE, Y. (2000). Live attenuated tetravalent dengue vaccine. Vaccine 18 (Suppl. 2), 44-47.
3. BISHT, H., CHUGH, D.A., RAJE, M., SWAMINATHAN, S.S., and KHANNA, N. (2002). Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J. Biotechnol. 99, 97-110.
4. BRAY, M., ZHAO, B.T., MARKOFF, L., ECKELS, K.H., CHANOCK, R.M., and LAI, C.J. (1989). Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J. Virol. 63, 2853-2856.
5. CHIA, S.C., LEUNG, P.S., LIAO, C.P., HUANG, J.H., and LEE, S.T. (2001). Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge. Microb. Pathog. 31, 9-19.
6. CLARKE, T. (2002). Dengue virus: break-bone fever. Nature 416, 672-674.
7. DELPEYROUX, F., CHENCINER, N., LIM, A., MALPIECE, Y., BLONDEL, B., CRAINIC, R., VAN DER WERF, S., and STREECK, R.E. (1986). A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 233, 472-475.
8. EDELMAN, R., WASSERMAN, S.S., BODISON, S.A., PUTNAK, R.J., ECKELS, K.H., TANG, D., KANESA-THASAN, N., VAUGHN, D.W., INNIS, B.L., and SUN, W. (2003). Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69, 48-60.
9. GUBLER, D.J., and CLARK, G.G. (1995). Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg. Infect. Dis. 1, 55-57.
10. GUIRAKHOO, F., PUGACHEV, K., ZHANG, Z., MYERS, G., LEVENBOOK, I., DRAPER, K., LANG, J., OCRAN, S., MITCHELL, F., PARSONS, M., BROWN, N., BRANDLER, S., FOURNIER, C., BARRERE, B., RIZVI, F., TRAVASSOS, A., NICHOLS, R., TRENT, D., and MONATH, T. (2004). Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78, 4761-4775.
11. HALSTEAD, S.B. (1980). Dengue haemorrhagic fever - a public health problem and a field for research. Bull. World Health Organ. 58, 1-21.
12. HENCHAL, E.A., GENTRY, M.K., MCCOWN, J.M., and BRANDT, W.E. (1982). Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am. J. Trop. Med. Hyg. 31, 830-836.
13. JONES, T. (2004). Technology evaluation: ChimeriVax-DEN, Acambis/Avends. Curr. Opin. Mol. Ther. 6, 443-450.
14. KANESA-THASAN, N., SUN, W., KIM-AHN, G., VAN ALBERT, S., PUTNAK, J.R., KING, A., RAENGSAKULSRACH, B., CHRISTSCHMIDT, H., GILSON, K., ZAHRADNIK, J.M., VAUGHN, D.W., INNIS, B.L., SALUZZO, J.F., and HOKE, C.H., JR. (2001). Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179-3188.
15. KANESA-THASAN, N., SUN, W., LUDWIG, G.V., ROSSI, C., PUTNAK, J.R., MANGIAFICO, J.A., INNIS, B.L., and EDELMAN, R. (2003). Atypical antibody responses in dengue vaccine recipients. Am. J. Trop. Med. Hyg. 69, 32-38.
16. KINNEY, R.M., and HUANG, C.Y. (2001). Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44, 176-197.
17. KUHN, R.J., ZHANG, W., ROSSMANN, M.G., PLETNEV, S.V., CORVER, J., LENCHES, E., JONES, C.T., MUKHOPADHYAY, S., CHIPMAN, P.R., STRAUSS, E.G., BAKER, T.S., and STRAUSS, J.H. (2002). Structure of dengue virus: implications for fiavivirus organization, maturation, and fusion. Cell 108, 717-725.
18. MODIS, Y., OGATA, S., CLEMENTS, D., and HARRISON, S.C. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100, 6986-6991.
19. MODIS, Y., OGATA, S., CLEMENTS, D., and HARRISON, S.C. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319.
20. MOTA, J., ACOSTA, M., ARGOTTE, R., FIGUEROA, R., MENDEZ, A., and RAMOS, C. (2005). Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23, 3469-3476.
21. PUTNAK, R., FEIGHNY, R., BURROUS, J., COCHRAN, M., HACKETT, C., SMITH, G., and HOKE, C. (1991). Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am. J. Trop. Med. Hyg. 45, 159-167.
22. REY, F.A., HEINZ, F.X., MANDL, C., KUNZ, C., and HARRISON, S.C. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298.
23. SABCHAREON, A., LANG, J., CHANTHAVANICH, P., YOKSAN, S., FORRAT, R., ATTANATH, P., SIRIVICHAYAKUL, C., PENGSAA, K., POJJAROEN-ANANT, C., CHAMBONNEAU, L., SALUZZO, J.F., and BHAMARAPRAVATI, N. (2004). Safety and immunogenicity of a three-dose regimen of two tetravalent live-attenuated dengue vaccines in five to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23, 99-109.
24. SABCHAREON, A., LANG, J., CHANTHAVANICH, P., YOKSAN, S., FORRAT, R., ATTANATH, P., SIRIVICHAYAKUL, C., PENGSAA, K., POJJAROEN-ANANT, C., CHOKEJINDACHAI, W., JAGSUDEE, A., SALUZZO, J.F., and BHAMARAPRAVATI, N. (2002). Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66, 264-272.
25. SIMMONS, M., MURPHY, G.S., and HAYES, C.G. (2001a). Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65, 159-161.
26. SIMMONS, M., MURPHY, G.S., KOCHEL, T., RAVIPRAKASH, K., and HAYES, C.G. (2001b). Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65, 420-426.
27. SIMMONS, M., NELSON, W.M., WU, S.J., and HAYES, C.G. (1998). Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58, 655-662.
28. SRIVASTAVA, A.K., PUTNAK, J.R., WARREN, R.L., and HOKE, C.H., JR. (1995). Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13, 1251-1258.
29. SUN, W., EDELMAN, R., KANESA-THASAN, N., ECKELS, K.H., PUTNAK, J.R., KING, A.D., HOUNG, H.S., TANG, D., SCHERER, J.M., HOKE, C.H., JR., and INNIS, B.L. (2003). Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69, 24-31.
30. VAN DER MOST, R.G., MURALI-KRISHNA, K., AHMED, R., and STRAUSS, J.H. (2000). Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74, 8094-8101.
31. WU, K.P., WU, C.W., TSAO, Y.P., KUO, T.W., LOU, Y.C., LIN, C.W., WU, S.C., and CHENG, J.W. (2003a). Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J. Biol. Chem. 278, 46007-46113.
32. WU, S.C., YU, C.H., LIN, C.W., and CHU, I.M. (2003b). The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 21, 2516-2522.
33. WU, S.F., LIAO, C.L., LIN, Y.L., YEH, C.T., CHEN, L.K., HUANG, Y.F., CHOU, H.Y., HUANG, J.L., SHAIO, M.F., and SYTWU, H.K. (2003c). Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21, 3919-3929.